Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eptacog Beta
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
Details : Eptacog Beta is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Thrombasthenia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 22, 2025
Lead Product(s) : Eptacog Beta
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union
Details : Cevenfacta (eptacog beta), a new recombinant coagulation Factor VIIa for treatment of bleeding episodes and for prevention of bleeding in those undergoing surgery or invasive procedures in adults and adolescents with haemophilia A or B with inhibitors.
Product Name : Cevenfacta
Product Type : Protein
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Recommends Cevenfacta to Control Bleeding Episodes in Patients With Congenital Haemophilia
Details : Positive opinions by CHMP were issued as a recommendation for marketing authorization was adopted for Cevenfacta (eptacog beta (activated)). Although FDA has approved SEVENFACT as first bypassing agent in over 20 years for patient with hemophilia A or B ...
Product Name : Cevenfacta
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Eptacog Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eptacog Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : HEMA Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
Product Name : Sevenfact
Product Type : Protein
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Eptacog Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : HEMA Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Anti-CD303 Antibodies in Autoimmune Diseases
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2017
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : University Hospital, Lille
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Antithrombin
Therapeutic Area : Hematology
Study Phase : Phase I
Recipient : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Details : Undisclosed
Product Name : ATryn
Product Type : Protein
Upfront Cash : Inapplicable
March 27, 2017
Lead Product(s) : Recombinant Human Antithrombin
Therapeutic Area : Hematology
Highest Development Status : Phase I
Recipient : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : LFB USA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 14, 2015
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : LFB USA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : LFB USA
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 19, 2015
Lead Product(s) : Coagulation Factor VIIa, Recombinant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : LFB USA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 16, 2014
Reset All
